These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 17998868)

  • 1. Steroid-free maintenance immunosuppression with rapamune and low-dose neoral in pancreas transplant recipients.
    Rajab A; Pelletier RP; Ferguson RM; Elkhammas EA; Bumgardner GL; Henry ML
    Transplantation; 2007 Nov; 84(9):1131-7. PubMed ID: 17998868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excellent clinical outcomes in primary kidney transplant recipients treated with steroid-free maintenance immunosuppression.
    Rajab A; Pelletier RP; Henry ML; Ferguson RM
    Clin Transplant; 2006; 20(5):537-46. PubMed ID: 16968478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
    Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
    Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy.
    Knight RJ; Kerman RH; McKissick E; Lawless A; Podder H; Katz S; Van Buren CT; Kahan BD
    Clin Transplant; 2008; 22(5):645-50. PubMed ID: 18657156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of renal transplant recipients treated with enteric-coated mycophenolic acid vs. mycophenolate mofetil as a switch agent using a primary steroid-free rapamune and microemulsion cyclosporine protocol.
    Pelletier RP; Soule J; Henry ML; Rajab A; Ferguson RM
    Clin Transplant; 2007; 21(4):532-5. PubMed ID: 17645715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymoglobulin, sirolimus, and reduced-dose cyclosporine provides excellent rejection prophylaxis for pancreas transplantation.
    Knight RJ; Kerman RH; Zela S; Podder H; Van Buren CT; Katz S; Kahan BD
    Transplantation; 2003 Apr; 75(8):1301-6. PubMed ID: 12717220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excellent short-term results with steroid-free maintenance immunosuppression in low-risk simultaneous pancreas-kidney transplantation.
    Freise CE; Kang SM; Feng S; Hirose R; Stock P
    Arch Surg; 2003 Oct; 138(10):1121-5; discussion 1125-6. PubMed ID: 14557130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with steroid-free maintenance immunosuppression in simultaneous pancreas-kidney transplantation.
    Freise CE; Kang SM; Feng S; Posselt A; Hirose K; Hirose R; Stock P
    Transplant Proc; 2004 May; 36(4):1067-8. PubMed ID: 15194370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excellent outcomes can be achieved in young pancreas transplant alone recipients by addition of sirolimus to maintenance immunosuppression regimen.
    Porubsky M; Gruessner AC; Rana A; Jie T; Gruessner RW
    Transplant Proc; 2014; 46(6):1932-5. PubMed ID: 25131074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis.
    Kandaswamy R; Melancon JK; Dunn T; Tan M; Casingal V; Humar A; Payne WD; Gruessner RW; Dunn DL; Najarian JS; Sutherland DE; Gillingham KJ; Matas AJ
    Am J Transplant; 2005 Jun; 5(6):1529-36. PubMed ID: 15888064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial outcomes of a steroid-free regimen with thymoglobulin induction in pancreas-kidney transplantation.
    Tanchanco R; Krishnamurthi V; Winans C; Wee A; Duclos A; Nurko S; Fatica R; Lard M; Poggio ED
    Transplant Proc; 2008 Jun; 40(5):1551-4. PubMed ID: 18589149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
    Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of immunosuppression minimization after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy.
    Knight RJ; Kerman RH; McKissick E; Lawless A; Podder H; Katz S; Van Buren CT; Kahan BD
    Transplant Proc; 2005 Oct; 37(8):3538-41. PubMed ID: 16298653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database.
    Tsai SF; Cheng CY; Shu KH; Wu MJ
    Transplant Proc; 2012 Jan; 44(1):190-2. PubMed ID: 22310612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in immunosuppression after pancreas transplantation: what is in the pipeline?
    Kimelman M; Brandacher G
    Curr Opin Organ Transplant; 2013 Feb; 18(1):76-82. PubMed ID: 23254700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.